Alkermes’ alixorexton granted orphan designation for idiopathic hypersomnia
Alkermes (ALKS)’ alixorexton was granted FDA orphan designation as a treatment of idiopathic hypersomnia, according to a post to the agency’s website.
Fiscal Year: January - December
Alkermes plc (ALKS), listed on the NASDAQ, has a market capitalization of $7.49B. As of Jun 12, 2026, the stock is trading at $44.92 per share@else an unavailable price , offering investors a clear view of its current market value. Alkermes plc is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 49.39, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Alkermes plc also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Alkermes plc (ALKS) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Alkermes plc is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Alkermes plc, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Alkermes plc is 33.76, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Alkermes plc (ALKS) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Alkermes plc (ALKS) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Alkermes plc (ALKS) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Alkermes plc. To access the full SS Score, consider upgrading your subscription.
Alkermes plc is a significant player in the industry sector, with a market capitalization of $7.49B and a competitive P/E ratio of 49.39. Investors should compare these metrics with industry peers to gauge whether Alkermes plc is outperforming or underperforming within its sector.
Alkermes (ALKS)’ alixorexton was granted FDA orphan designation as a treatment of idiopathic hypersomnia, according to a post to the agency’s website.
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
RBC Capital raised the firm’s price target on Alkermes (ALKS) to $56 from $45 and keeps an Outperform rating on the shares. While the developmental focus for orexin agonists has…
Alkermes (ALKS) announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, Jun...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanza...
Baird analyst Luke Herrmann raised the firm’s price target on Alkermes (ALKS) to $48 from $45 and keeps an Outperform rating on the shares. The firm updated its model following…
Alkermes (ALKS) announced positive topline results from the REVITALYZ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ ex...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study eva...
UBS analyst Ashwani Verma raised the firm’s price target on Alkermes (ALKS) to $48 from $42 and keeps a Buy rating on the shares. Alkermes is gaining increased investor attention…
Needham raised the firm’s price target on Alkermes (ALKS) to $50 from $45 and keeps a Buy rating on the shares after its Q1 results. The stock is up significantly…
Reports Q1 revenue $392.9M, consensus $361.38M.
Sees FY26 adjusted EBITDA $370M-$410M
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first qua...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company's first quarter...
Alkermes (ALKS) announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 at the American Academy of Neurology 2026 Annual…
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the ...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 352.00M | Analyst x1 | |
| 2027 | 474.02M | 34.67% | Analyst x2 |
| 2028 | 693.86M | 46.38% | Analyst x2 |
| 2029 | 731.84M | 5.47% | Analyst x2 |
| 2030 | 792.91M | 8.34% | Analyst x2 |
| 2031 | 829.90M | 4.67% | Est @4.7% |
| 2032 | 863.63M | 4.07% | Est @4.1% |
| 2033 | 895.04M | 3.64% | Est @3.6% |
| 2034 | 922.99M | 3.12% | Est @3.1% |
| 2035 | 949.99M | 2.93% | Est @2.9% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 405.64M | 1.00 | 405.64M |
| 2025A | 480.33M | 1.00 | 480.33M |
| 2026E | 352.00M | 1.08 | 326.84M |
| 2027E | 474.02M | 1.16 | 408.68M |
| 2028E | 693.86M | 1.25 | 555.45M |
| 2029E | 731.84M | 1.35 | 543.98M |
| 2030E | 792.91M | 1.45 | 547.24M |
| 2031E | 829.90M | 1.56 | 531.83M |
| 2032E | 863.63M | 1.68 | 513.89M |
| 2033E | 895.04M | 1.81 | 494.52M |
| 2034E | 922.99M | 1.95 | 473.50M |
| 2035E | 949.99M | 2.10 | 452.52M |
| Terminal | 18.73B | 2.10 | 8.92B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.